Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide

Leuk Lymphoma. 2010 May;51(5):937-40. doi: 10.3109/10428191003695660.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Drug Resistance, Neoplasm*
  • Female
  • Frail Elderly
  • Humans
  • Male
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Prognosis
  • Pyrazines / administration & dosage
  • Salvage Therapy
  • Treatment Outcome

Substances

  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone
  • Cyclophosphamide